| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.06▲ | 1.06▲ | 1.06▲ | 1.07▲ | 1.17▼ |
| MA10 | 1.06▲ | 1.05▲ | 1.05▲ | 1.07▲ | 1.40▼ |
| MA20 | 1.05▲ | 1.04▲ | 1.05▲ | 1.15▼ | 1.77▼ |
| MA50 | 1.04▲ | 1.06▲ | 1.07▼ | 1.47▼ | 1.91▼ |
| MA100 | 1.06▲ | 1.08▼ | 1.13▼ | 1.84▼ | 3.26▼ |
| MA200 | 1.07▲ | 1.15▼ | 1.20▼ | 1.94▼ | 26.40▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.005▲ | 0.005▲ | 0.017▲ | -0.090▼ |
| RSI | 71.211▲ | 60.293▲ | 53.668▲ | 36.148▼ | 34.387▼ |
| STOCH | 88.889▲ | 91.667▲ | 90.476▲ | 25.424 | 3.255▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -74.194 | -97.492▼ |
| CCI | 189.189▲ | 155.556▲ | 140.075▲ | -68.678 | -82.585 |
|
Thursday, August 14, 2025 03:16 PM
Phio Pharmaceuticals is focused on developing next-generation cancer therapies using its proprietary INTASYL technology. The INTASYL platform enables the silencing of specific genes used by cancer ...
|
|
Thursday, August 14, 2025 01:14 PM
Phio's ongoing Phase 1b dose escalation clinical trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous ...
|
|
Monday, March 31, 2025 08:59 AM
PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/12/25 | 1.07 | 1.08 | 1.03 | 1.08 | 207,315 |
| 24/12/25 | 1.02 | 1.05 | 1.02 | 1.05 | 100,760 |
| 23/12/25 | 1.095 | 1.10 | 1.00 | 1.03 | 1,190,882 |
| 22/12/25 | 1.08 | 1.18 | 1.08 | 1.10 | 401,762 |
| 19/12/25 | 1.09 | 1.10 | 1.04 | 1.07 | 422,634 |
| 18/12/25 | 1.05 | 1.13 | 1.05 | 1.06 | 324,924 |
| 17/12/25 | 1.07 | 1.13 | 1.06 | 1.07 | 210,275 |
| 16/12/25 | 1.07 | 1.09 | 1.04 | 1.08 | 187,883 |
| 15/12/25 | 1.14 | 1.14 | 1.075 | 1.09 | 120,567 |
| 12/12/25 | 1.16 | 1.17 | 1.12 | 1.12 | 183,973 |
|
|
||||
|
|
||||
|
|